dpp-4 inhibitor with glp-1 receptor agonist combination not recommended ada Frontiers ADA 2025 guidelines for diabetes
Description
doi:10.1007/s40259-015-0143-4 68
The benefits of leveraging our comprehensive capabilities are far from theoretical
10.1016/j.bbr.2009.06.035 2 AbbottC
Cell Metab (2013) 17(6):81937
Zhou B, Dong C, Zhao B, Su X, Luo Y, Xie L, et al
Consumers should verify that products comply with UK food safety standards
